Inventor · disambiguated record
Tatsuya Kawa
Also filed as: KAWA TATSUYA
3 granted patents·7 pending applications·3 citations·filing 2018–2024
55Inventor score
Files withCHUGAI PHARMACEUTICAL CO LTD10
Top patents by PatentIndex Score
10 records- 0183US12030955B2Polypeptide including antigen-binding domain and carrying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Jul 9, 2024·2 cites·19 claims
- 0277US12435137B2Antigen-binding molecule containing two antigen-binding domains that are linked to each otherCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Granted Oct 7, 2025·1 cites·12 claims
- 0374US2025026852A1Polypeptide including antigen-binding domain and carrying sectionCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0462US2024270806A1Protease-activated cytokineCHUGAI PHARMACEUTICAL CO LTD·Filed 2024·Application pending·0 cites
- 0553US2022315909A1Protease substrate, and polypeptide including protease cleavage sequenceCHUGAI PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 0652US12195528B2Ligand-binding molecule having adjustable ligand-binding activityCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Granted Jan 14, 2025·0 cites·18 claims
- 0750US2023121511A1Method for producing multispecific antigen-binding moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0846US2023348528A1Methods for producing and/or enriching recombinant antigen-binding moleculesCHUGAI PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 0945US2021253672A1Ligand-binding molecule containing single domain antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
- 1041US2021188957A1Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-moleculeCHUGAI PHARMACEUTICAL CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tatsuya Kawa files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →